Skip to main
VANI

VANI Stock Forecast & Price Target

VANI Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vivani Medical Inc is advancing its NPM-139 candidate, which has shown potential to enhance the safety and tolerability of established treatments like semaglutide, potentially reducing therapy discontinuation rates among patients. Data supporting a significant weight loss of approximately 20% sustained over six months bolsters the case for NPM-139's clinical development. This positive outcome not only suggests improved patient compliance but also positions Vivani Medical favorably within the competitive landscape of chronic disease management solutions.

Bears say

Vivani Medical Inc faces significant risks related to the development and commercialization of its lead product, NPM-139, including the potential failure in clinical trials and the challenges in securing necessary regulatory approvals. Additionally, the company's outlook is further complicated by uncertainties regarding the market size, penetration rate, and competitive landscape, which could hinder NPM-139's commercial success. The threat of dilution also poses a financial risk, potentially impacting shareholder value as the company seeks to fund its ongoing operations and research initiatives.

VANI has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vivani Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vivani Medical Inc (VANI) Forecast

Analysts have given VANI a Strong Buy based on their latest research and market trends.

According to 1 analysts, VANI has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vivani Medical Inc (VANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.